WebApr 12, 2024 · To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an intravenous (IV) infusion over 4 hours, once weekly for 3 weeks, followed by a 1 week rest, in a 28-day cycle to pediatric patients with recurrent/refractory solid tumors, including non-Hodgkin lymphoma and desmoid tumors. WebJun 1, 2024 · The poster, titled, "Results of a phase I dose escalation study of a tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable …
Current management and recent progress in desmoid tumors
WebJun 2, 2024 · 11523 Background: Desmoid tumors are known to have increased nuclear β-catenin levels. Tegavivint selectively disrupts the interaction of β-catenin and TBL1/ … WebJul 28, 2024 · HOUSTON, July 28, 2024 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that enrollment has commenced in its multicenter Phase 2a dose expansion clinical study of Tegavivint, a novel, potent and selective nuclear β … child safety maryborough qld phone number
Iterion Therapeutics Announces Initiation of Phase 1/2 ... - BioSpace
WebMar 4, 2024 · Tegavivint (BC-2059) is under development for the treatment of desmoid tumors, metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), acute myelocytic leukemia, multiple myeloma, solid tumors including osteosarcoma, r/r non-Hodgkin lymphoma and desmoid tumors, Ewing sarcoma, liver … WebApr 8, 2024 · Results from Phase 1 Dose Escalation Study of Tegavivint in Patients with Desmoid Tumors to Be Featured as in a Poster Presentation on April 12, 2024. HOUSTON, April 8, 2024 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that … WebMar 4, 2024 · Tegavivint (BC-2059) is under development for the treatment of desmoid tumors, metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), acute myelocytic leukemia, multiple myeloma, solid tumors including osteosarcoma, r/r non-Hodgkin lymphoma and desmoid tumors, Ewing sarcoma, liver … child safety locks on cars